Bicara Therapeutics (NASDAQ:BCAX) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS

Bicara Therapeutics (NASDAQ:BCAX) issued its earnings results on Thursday. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08), Zacks reports.

Bicara Therapeutics Trading Up 0.1 %

NASDAQ BCAX traded up $0.02 on Friday, reaching $13.42. The stock had a trading volume of 58,204 shares, compared to its average volume of 457,303. Bicara Therapeutics has a 12-month low of $11.10 and a 12-month high of $28.09. The company’s 50-day moving average is $13.01.

Analysts Set New Price Targets

Several research analysts have recently issued reports on BCAX shares. Wedbush reaffirmed an “outperform” rating and set a $31.00 price objective on shares of Bicara Therapeutics in a research report on Thursday. HC Wainwright upped their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, January 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $36.50.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.